Cost regulators for NHS therapies in England and Wales have now published final guidelines backing the use of LEO Pharma’s Kyntheum as an option for treating severe plaque psoriasis. Cost regulators ...

While you might have heard about a skin condition called psoriasis, you could be unaware of some of its causes and how to treat it. Whether it’s you or someone you know who is experiencing psoriasis, ...

Patients with severe plaque psoriasis living in England and Wales should now get access to Celgene's Otezla on the NHS like their counterparts in Scotland, after cost regulators concluded that the ...

Deucravacitinib has been accepted by the Scottish Medicines Consortium (SMC) for use in Scotland for the treatment of adults with moderate to severe plaque psoriasis who are eligible for systemic ...

Psoriasis is a chronic skin condition characterised by thick, flaking patches of skin. These patches normally appear on elbows, knees, scalp and lower back, but can appear anywhere on the body.

standard assessments show that their psoriasis is severe and is affecting their quality of life, and their psoriasis has not improved with conventional systemic treatments and phototherapy, or they ...

(Uxbridge, Middlesex, 28 th June 2023) - Bristol Myers Squibb (BMS) today announced that the National Institute for Health and Care Excellence (NICE) has recommended deucravacitinib, a once-daily oral ...

Psoriasis is caused by a build-up of skin cells Signs include flaky patches of skin Triggers include stress, sunburn, or drinking too much alcohol Psoriasis could be treated with creams or medication ...

The survey also found 60% of units had no clinical psychology services to help patients - despite research suggesting as many as one in 10 is so distressed by their condition that they consider ...

their psoriasis has not improved with conventional systemic treatments and phototherapy, or they have had side effects with these treatments in the past or there is a reason why they cannot have them, ...